BridgeBio Pharma (BBIO) Total Current Liabilities (2018 - 2026)

BridgeBio Pharma has reported Total Current Liabilities for 9 years, with the latest figure at $816.4 million in Q1 2026.

• Quarterly Total Current Liabilities rose 436.72% year-over-year to $816.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $816.4 million (up 436.72% YoY) and the FY2025 annual result came in at $288.0 million, up 86.51% from the prior year.
• Total Current Liabilities improved to $816.4 million in Q1 2026 per BBIO's latest filing, from $288.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $816.4 million in Q1 2026 and troughed at $96.6 million in Q1 2023.
• A 5-year average of $185.9 million and a median of $141.2 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities declined 21.99% in 2023, then jumped 436.72% in 2026.
• Over 5 years, Total Current Liabilities stood at $121.4 million in 2022, then increased by 18.46% to $143.8 million in 2023, then climbed by 7.34% to $154.4 million in 2024, then jumped by 86.51% to $288.0 million in 2025, then soared by 183.49% to $816.4 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $816.4 million, $288.0 million, and $216.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.